Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

151.02 +0.02 (+0.02%)
Streaming Delayed Price Updated: 2:48 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 986
Open 151.02
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 151.00
Today's Range 149.00 - 151.02
52wk Range 118.16 - 152.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 stocks that crushed earnings estimates and still tanked
Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks 
Via MarketBeat
Exposures COVID-19
AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization
Earlier today, AstraZeneca plc (NASDAQ: AZN)  
Via Benzinga

Performance

YTD
+13.71%
+13.71%
1 Month
+11.21%
+11.21%
3 Month
+15.07%
+15.07%
6 Month
+23.02%
+23.02%
1 Year
+3.22%
+3.22%

More News

Read More
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
Via Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Via Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
Via Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
Via Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
Via Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
Via Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
Via Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
Via Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
Via Benzinga
AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
Via Benzinga
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
Via Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
Via Benzinga
AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
Via Benzinga
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Why AstraZeneca Shares Are Trading Higher Today?
Via Benzinga
Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
Via Benzinga
AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.